Search results
Results from the WOW.Com Content Network
Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. [6] It was considered the largest corporate merger in history during that time. [6] The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes (new skills). [6]
Novartis v. Union of India & Others is a landmark decision by a two-judge bench of the Indian Supreme Court on the issue of whether Novartis could patent Gleevec in India, and was the culmination of a seven-year-long litigation fought by Novartis. The Supreme Court upheld the Indian patent office's rejection of the patent application.
The 100 known most prolific inventors based on worldwide utility patents are shown in the following table. While in many cases this is the number of utility patents granted by the United States Patent and Trademark Office, it may include utility patents granted by other countries, as noted by the source references for an inventor.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Help; Learn to edit; Community portal; Recent changes; Upload file
They applied for patent in 1991, but granted only in 2002. In 1992 they got it registered as a new drug. Novartis then noticed the new drug and made a deal for mass production. [1] In 1999 Novartis obtained the international licensing rights and gave the brand name Coartem. It was approved by the US Food and Drug Administration in 2009. [4]
Jimenez joined Novartis in 2007 as Division Head of Novartis Pharmaceutical and was named CEO in 2010 [7] by his predecessor and Chairman Daniel Vasella. [8]During his time at Novartis, Jimenez increasingly applied standard business metrics to pharma cash flow, purchasing and competitive bidding, confident that his experience in consumer goods would help to realize improvements in Novartis ...
For a list of notable patent attorneys, see list of patent attorneys and agents. For a list of notable patent examiners and clerks, see patent examiner. Although this list is not intended to include inventors, patent attorneys and patent clerks, those may also be inserted in this list if they made a durable impact on patent law, or patent ...
Paul Herrling is the head of corporate research at Novartis and the chairman of board of the Novartis Institute for Tropical Diseases, Singapore [1] since 2002. [2] Prior to this, he was the head of Global Research of Novartis Pharma.